Background:
The World Health Organization (WHO) was notified in December 2019 about COVID-19, a new coronavirus detected in Wuhan, China, as the cause of an outbreak of a lower respiratory tract infection.1 The WHO then declared it a Public Health Emergency of International Concern on 30 January 2020. On 11 February 2020, the WHO announced a name for the new coronavirus disease: COVID-19.2 To date, there are 8,860,331 cases of COVID-19 globally including 465,740 deaths. The highest number of cases are in America at 4,370,519 with 4,996 deaths. In the Eastern Mediterranean WHO region, there are 914,518 cases with 20,531 deaths. Sudan is a member of the Eastern Mediterranean WHO region and reported 8,580 with 521 deaths.3   The virus mainly causes pneumonia and acute respiratory distress syndrome4, as well as a multi-organ disease affecting the kidneys, brain, heart, liver and other organs.5 It leads to serious complications such as a cytokine storm, septic shock, blood clots and immune-mediated injuries.6-8 Neurological manifestations and complications are common due to COVID-19. It affects higher functions, cranial nerves and the motor system. It can lead to headaches, convulsions, mental and psychological changes, delirium and insomnia. Guillain Barre syndrome can occur as a consequence of or in co-incidence with COVID-19, but it is very rare.9-11 The authors report a case of Guillain Barre syndrome as an example of a success story in managing a complicated case of COVID-19 in an elderly male with signs of a poor prognosis.